Lincoln Pharmaceuticals Limited (LPL) is engaged in the business of manufacturing, marketing and distribution of pharmaceutical products. Financial Results: Lincoln Pharmaceuticals Ltd
Categories
Pharmaceutical
Natco Pharma Ltd Q1FY24; 31% rise in Profits
NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products
Medicamen Biotech Ltd Q1FY24; 23% rise in Profits
Medicamen Biotech Ltd develops and markets a wide range of branded and generic formulations in the pharmaceutical industry. Financial Results: Medicamen Biotech
Piramal Pharma Ltd Q1FY24; 18% rise in Revenue
Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments(1) Contract development and
Lupin Ltd Q1FY24; 29% rise in Revenue
Lupin is engaged in the business of Manufacture of Pharmaceuticals. Financial Results: Lupin Ltd reported Revenues for Q1FY24 of ₹4,814.00 Crores up
Neuland Laboratories Ltd Q1FY24; 520% rise in Profits
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. Financial Results: Neuland
Jagsonpal Pharmaceuticals Ltd Q1FY24; 156% rise in Profits
Jagsonpal Pharmaceuticals Ltd is primarily engaged in the manufacturing and trading of pharmaceutical products and APIs. It has operations in India and
Lyka Labs Ltd Q1FY24; 17% fall in Revenue
Lyka labs Ltd is a pharmaceutical company engaged in development, manufacturing and marketing of pharmaceutical products. It has a well-diversified business model
RPG Life Sciences Ltd Q1FY24; 22% rise in Profits
RPG Life Sciences Ltd is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) in
Laurus Labs Ltd Q1FY24; 94% fall in Profits
Laurus Labs is principally engaged in offering a broad and integrated portfolio of Active Pharmaceuticals Ingredients (API) including intermediates, Generic Finished dosage
Novartis India Ltd Q1FY24; 62% fall in Profits
Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods.It imports various medicines to India from
Aurobindo Pharma: Driving Growth in the Pharmaceutical Industry
Stock Data: TickerNSE: AUROPHARMAExchangeNSEIndustryPHARMACEUTICALS Price Performance: Last 5 Days+2.46%YTD+54.04%Last 12 Months+26.40% Company Description: Aurobindo, a company based in Hyderabad since 1986, focuses
Piramal Pharma Q4FY23 Earnings Story
Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments(1) Contract development and
Natco Pharma Q4FY23 Earnings Story
NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products
Jubilant Pharmova Q4FY23 Earnings Story
The three business components of Jubilant Pharmova Ltd, which include medicines, contract research and development services, and patented new therapies, make up
Pfizer Limited Q4FY23 Earnings Story
Pharmaceutical product manufacture, marketing, trade, and export are all activities of Pfizer Ltd. It produces goods in-house and also works with several
Medico Remedies Q4FY23 Earnings Story
Medico Remedies is engaged in the business of Manufacture of allopathic pharmaceutical preparations. Financial Results: Medico Remedies Limited reported Total Income for
Neuland Laboratories Q4FY23 Earnings Story
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. Financial Results: Neuland
Orchid Pharma Limited Q4FY23 Earnings Story
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It
Lupin Limited Q4FY23 Earnings Story
Lupin manufactures pharmaceuticals as a line of business. Globally, APIs, biotechnology products, and generic formulations are all developed and marketed by Lupin
Syngene International Ltd (SYNGENE) Q4 FY23 Earnings Concall Transcript
Syngene International Ltd (NSE:SYNGENE) Q4 FY23 Earnings Concall dated Apr. 27, 2023. Corporate Participants: Avantika Mishra -- Investor Relations Jonathan Hunt -- Managing Director and Chief